Re-Growing Beta Cells, Potential Type I Diabetes Treatment

Re-Growing Beta Cells, Potential Type I Diabetes Treatment

Top of Mind with Julie Rose - Radio Archive, Episode undefined

  • Sep 18, 2018 9:00 pm
  • 12:25 mins

Guest: Jeffery Tessem, PhD, Professor of Nutrition, Dietetics & Food Science, Head of the Tessem Diabetes Research Lab, Brigham Young University One in ten Americans have diabetes and most of that is Type 2 diabetes, which means the body doesn’t use insulin properly to keep blood sugar levels in check. Proper exercise and diet can prevent most people from getting Type 2 diabetes. That’s not true for the other type of diabetes – Type 1, which is sometimes called “juvenile diabetes” because it often occurs in childhood. There is no cure yet for Type 1 diabetes, but researchers have zeroed in on something in the body called “beta cells.”

Other Segments

How Drug Companies Continue to Make the Opioid Crisis Worse

18 MINS

Guest: Robin Feldman, JD, Professor of Law, Director of the Institute for Innovation Law, University of California A prominent player in America’s opioid abuse problem, Purdue Pharma, is facing more than a thousand lawsuits from states and cities over its alleged role in fueling the opioid crisis with its prescription painkiller OxyContin. Now, Purdue notes that OxyContin accounts for less than two percent of opioid in the US. But it used to be much higher. And investigative reporting in a range of publications has shown how aggressively Purdue worked to expand opioid use in the US, even as the overdose crisis escalated. The Financial Times recently reported that a company affiliated with Purdue Pharma patented a new drug earlier this year to treat opioid addiction, meaning it could potentially profit off both sides of the opioid epidemic.

Guest: Robin Feldman, JD, Professor of Law, Director of the Institute for Innovation Law, University of California A prominent player in America’s opioid abuse problem, Purdue Pharma, is facing more than a thousand lawsuits from states and cities over its alleged role in fueling the opioid crisis with its prescription painkiller OxyContin. Now, Purdue notes that OxyContin accounts for less than two percent of opioid in the US. But it used to be much higher. And investigative reporting in a range of publications has shown how aggressively Purdue worked to expand opioid use in the US, even as the overdose crisis escalated. The Financial Times recently reported that a company affiliated with Purdue Pharma patented a new drug earlier this year to treat opioid addiction, meaning it could potentially profit off both sides of the opioid epidemic.